| Literature DB >> 30521521 |
Ruth Backman1,2, Robbie Foy3, Peter J Diggle4,5, Rachel Kneen1,6, Ava Easton1,7, Sylviane Defres1,8,9, Fiona McGill1,8,9, Benedict Daniel Michael1,10, Tom Solomon1,9,10.
Abstract
OBJECTIVE: To determine whether a tailored multifaceted implementation strategy improves the initial management of patients with suspected encephalitis.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30521521 PMCID: PMC6283633 DOI: 10.1371/journal.pone.0202257
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1ENCEPH Cluster RCT CONSORT flow diagram.
Fig 1 represents recruitment through both control and intervention arms in this study.
Characteristics of hospital sites.
| Intervention | Control | |
|---|---|---|
| 13 | 11 | |
| 266 | 223 | |
| 20.5 | 20.3 | |
| 133 (50%) | 121 (54.3%) | |
| 45 (30, | 51 (27.6, | |
| 206 (77.4%) | 188 (84.3%) | |
| 37 (13.9%) | 21 (9.4%) | |
| 47 (17.7%) | 42 (18.8%) | |
| 86 (32.3%) | 72 (32.3%) | |
| 39 (14.7%) | 33 (14.8%) | |
| 132 (49.6%) | 109 (48.9%) | |
| 9 (3.4%) | 9 (4.0%) |
Absolute numbers are displayed for all variables with percentages shown in brackets. Percentages were calculated using the patient variable against the number of patients within the arm.
Crude trial primary and secondary outcomes unadjusted for clustering or covariate effects.
| Intervention | Control | |||||||
|---|---|---|---|---|---|---|---|---|
| Number eligible | Number meeting outcome | Percentage | Number eligible | Number meeting outcome | Percentage | Percentage difference (95% confidence interval) | ||
| 266 | 36 | 13.53 | 223 | 33 | 14.80 | -1.26 (-7.48, 4.95) | ||
| 206 | 25 | 12.14 | 190 | 29 | 15.26 | -3.13 (-9.91, 3.66) | ||
| 60 | 11 | 18.33 | 33 | 4 | 12.12 | 6.21 (-8.62, 21.04) | ||
| 266 | 81 | 30.45 | 223 | 63 | 28.25 | 2.20 (-5.89, 10.29) | ||
| 206 | 52 | 25.24 | 190 | 52 | 27.37 | -2.13 (-10.81, 6.56) | ||
| 60 | 29 | 48.33 | 33 | 11 | 33.33 | 15.00 (-5.46, 35.46) | ||
| 266 | 70 | 26.32 | 223 | 66 | 29.60 | -3.28 (-11.27, 4.71) | ||
| 206 | 48 | 23.30 | 190 | 58 | 30.53 | -7.23 (-15.96, 1.50) | ||
| 60 | 22 | 36.67 | 33 | 8 | 24.24 | 12.42 (-6.61, 31.46) | ||
| 266 | 234 | 87.97 | 223 | 209 | 93.72 | -5.75 (-10.79, -0.71) | ||
| 206 | 180 | 87.38 | 190 | 178 | 93.68 | -6.31 (-12.01, -0.60) | ||
| 60 | 54 | 90.00 | 33 | 31 | 93.94 | -3.94 (-15.07, 7.19) | ||
| 266 | 86 | 32.33 | 223 | 78 | 35.00 | -2.65 (-11.06, 5.77) | ||
| 206 | 65 | 31.55 | 190 | 65 | 34.21 | -2.66 (-11.92, 6.60) | ||
| 60 | 21 | 35.00 | 33 | 13 | 39.39 | -4.39 (-24.98, 16.19) | ||
| 266 | 182 | 68.42 | 223 | 175 | 78.48 | -10.05 (-17.82, -2.29) | ||
| 206 | 141 | 68.45 | 190 | 147 | 77.37 | -8.92 (-17.62, -0.22) | ||
| 60 | 41 | 68.33 | 33 | 28 | 84.85 | -16.52 (-33.49, 0.46) | ||
| 266 | 153 | 57.52 | 223 | 120 | 53.81 | 3.71 (-5.13, 12.54) | ||
| 206 | 129 | 62.62 | 190 | 112 | 58.95 | 3.67 (-5.95, 13.30) | ||
| 60 | 24 | 40.00 | 33 | 8 | 24.24 | 15.76 (-3.41, 34.93) | ||
| 266 | 136 | 51.13 | 223 | 131 | 58.74 | -7.62 (-16.44, 1.21) | ||
| 206 | 122 | 59.22 | 190 | 119 | 62.63 | -3.41 (-13.02, 6.20) | ||
| 60 | 14 | 23.33 | 33 | 12 | 36.36 | -13.03 (-32.62, 6.56) | ||
Primary and secondary outcomes for control and intervention arms across all adults and paediatric patients. Number eligible shows denominator.
Maximum likelihood estimates of intervention effect for secondary outcomes.
| Secondary outcome | Estimate | Standard error | p-value |
|---|---|---|---|
| Lumbar puncture performed within 12 hours unless there was a clinical contraindication | 0.30 | 0.73 | |
| Lumbar puncture at any time | 0.43 | 0.08 | |
| CT or MRI within 24 hours | 0.38 | 0.66 | |
| Lumbar puncture with CSF/serum glucose ratio calculated | 0.43 | 0.78 | |
| Lumbar puncture and a sample taken for HSV PCR | 0.70 | 0.82 | |
Estimates of fixed effects in the model for the secondary outcome, correct administration of aciclovir.
| Parameter | Estimate | Standard error | p-value |
|---|---|---|---|
| Intercept | 0.19 | 0.00 | |
| Block | 0.21 | 0.74 | |
| Treatment | 0.23 | 0.60 | |
| Age group | 0.41 | 0.01 | |
Maximum likelihood estimates of interaction effect between treatment and age group for secondary outcomes.
| Lumbar puncture performed within 12 hours unless there was a clinical contraindication | 0.62 | 0.21 | |
| Lumbar puncture at any time | 1.01 | 0.92 | |
| CT or MRI within 24 hours | 0.62 | 0.49 | |
| Lumbar puncture with CSF/serum glucose ratio calculated | 0.69 | 0.54 | |
| Lumbar puncture and a sample taken for HSV PCR | 1.18 | 0.60 | |